EMVision Medical Devices Limited announced a strategic AUD 15.28 million investment from Keysight Technologies Inc, to bolster the former’s neuroimaging technology and its potential to revolutionise diagnosis and treatment outcomes for neurological disorders.
Upon completion of the placement, Keysight will emerge as a substantial shareholder in EMVision, holding approximately 8.73 per cent of the company, EMVision said in a media release.
Keysight, a technology giant listed on the NYSE with a market capitalisation of approximately USD 26 billion, is renowned for its expertise in radiofrequency test and measurement technology.
This marks Keysight’s inaugural foray into major investments within the global medical device manufacturing and imaging sector, highlighting its belief in the clinical and commercial promise of EMVision’s innovative solutions.
EMVision’s portable brain-scanning technology, developed over five years of successful collaboration with Keysight, aims to enhance stroke and neurological disorder diagnosis and treatment by introducing a novel imaging modality at the point of care.
EMVision CEO & MD Scott Kirkland expressed his satisfaction, stating that the company is pleased to welcome Keysight as a major strategic investor, emphasising the longstanding relationship between the two entities and their successful joint showcase at RSNA 2023.
He highlighted, “This investment reflects Keysight’s increasing commitment to helping drive breakthroughs in digital healthcare and emerging point-of-care imaging.”
“It further supports our vision to revolutionise stroke diagnosis and monitoring in a multi-billion-dollar market and allows us to do so more quickly through expanded trials and data inputs,” Kirkland remarked.
Huei Sin, president of the Electronic Industrial Solutions Group at Keysight Technologies, expressed delight at strengthening the relationship with EMVision to drive groundbreaking advancements in medical imaging technology.
He stated, “Keysight’s technology leadership, particularly our industry leading data acquisition speeds, alongside EMVision’s brain scanning innovation, strategically positions our companies to spearhead significant developments in cutting-edge imaging solutions.”
EMVision’s innovative technology utilises ultra-high frequency radio signals to deliver breakthroughs in neuroimaging.
Central to this advancement is the pivotal role played by Keysight’s Vector Network Analyzers, powering the portable brain scanner and contributing significantly to the device’s functionality.
